B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity-Reference-Cited by-同舟云学术

B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity

Published:2024-09-02 Issue: Volume: Page:
ISSN:2328-9503
Container-title:Annals of Clinical and Translational Neurology
language:en
Short-container-title:Ann Clin Transl Neurol

Author:

Bennett Jeffrey L.¹^ORCID,Pittock Sean J.²^ORCID,Paul Friedemann³^ORCID,Kim Ho Jin⁴^ORCID,Irani Sarosh R.⁵⁶^ORCID,O'Connor Kevin C.⁷,Patterson Kristina R.⁸,Smith Michael A.⁸,Gunsior Michele⁸,Mittereder Nanette⁸,Rees William A.⁸,Cimbora Daniel⁸,Cree Bruce A. C.⁹^ORCID

Affiliation:

1. Departments of Neurology and Ophthalmology Programs in Neuroscience and Immunology, University of Colorado School of Medicine, Anschutz Medical Campus Aurora Colorado USA

2. Neurology, Laboratory Medicine and Pathology Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic Rochester Minnesota USA

3. Experimental and Clinical Research Center Max Delbrueck Center for Molecular Medicine and Charité – Universitätsmedizin Berlin Germany

4. Department of Neurology Research Institute and Hospital of National Cancer Center Goyang Republic of Korea

5. Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences University of Oxford Oxford UK

6. Department of Neurology Mayo Clinic Jacksonville Florida USA

7. Department of Neurology and Immunobiology Yale School of Medicine New Haven Connecticut USA

8. Horizon Therapeutics (now Amgen Inc., Thousand Oaks, California, USA) Gaithersburg Maryland USA

9. UCSF Weill Institute for Neurosciences, Department of Neurology University of California San Francisco San Francisco California USA

Abstract

AbstractThis post hoc analysis of the randomized, placebo‐controlled N‐MOmentum study (NCT02200770) of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD) evaluated relationships between circulating B‐cell subsets and aquaporin‐4 immunoglobulin G (AQP4‐lgG) titers and attacks. Among participants receiving placebo, CD20+ and CD27+ B‐cell counts were modestly increased from the pre‐attack visit to attack; plasmablast/plasma cell gene signature was increased from baseline to the pre‐attack visit (p = 0.016) and from baseline to attack (p = 0.009). With inebilizumab treatment, B‐cell subset counts decreased and did not increase with attacks. No difference in change of AQP4‐IgG titers from baseline to time of attack was observed.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acn3.52171

Reference24 articles.

1. B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets

2. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica

3. More Efficient Complement Activation by Anti–Aquaporin-4 Compared With Anti–Myelin Oligodendrocyte Glycoprotein Antibodies

4. Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD

5. Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study